Why is proline used so heavily in these peptides?

It constrains backbone conformation and confers protease resistance, because peptidases recognise a backbone geometry proline does not present.

How enriched are these sequences?

Five to nine times. Proline is about 5% of residues generally; Selank is 43%, Semax 29% and BPC-157 27%.

Yes. A constrained backbone cannot adopt whichever conformation a receptor requires unless that happens to be the constrained one.

Selank (Tuftsin Analogue)

Why Proline Keeps Appearing in These Sequences

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Proline appears at unusually high frequency across several compounds in this catalogue. Misiura and colleagues reviewed proline-containing peptides in Biofactors in 2019, treating them as a class with shared structural and functional properties rather than unrelated compounds.

Key facts

Review: Misiura 2019, Biofactors (PMID 31430415)
Selank: 3 prolines in 7 residues — 43%
Semax: 2 prolines in 7 residues — 29%
BPC-157: 4 prolines in 15 residues — 27%
Typical in proteins: About 5%
Shared consequence: Conformational constraint, protease resistance

What makes proline structurally unusual

Its side chain loops back and bonds to the backbone nitrogen, forming a ring. That removes the amide hydrogen every other residue carries, so proline cannot donate a hydrogen bond in the way secondary structure requires, and it constrains rotation around the backbone. It is the only residue that alters the backbone itself rather than decorating it.

Why that produces protease resistance

Peptidases recognise backbone geometry, and the constrained conformation around proline does not present the arrangement most of them require. Bonds adjacent to proline are therefore cleaved by a restricted set of enzymes rather than the general population, which is why proline-rich sequences persist longer than their length would suggest.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

How enriched these sequences actually are

Proline is roughly 5% of residues across proteins generally. Selank is 43% proline, Semax 29% and BPC-157 27% — between five and nine times enriched. That is not a subtle preference. In Selank's and Semax's cases the enrichment was deliberately engineered; in BPC-157's it is a property of the natural sequence.

The Pro-Gly-Pro motif specifically

Both Selank and Semax carry the same C-terminal Pro-Gly-Pro extension appended to entirely different parent peptides — tuftsin in one case, an ACTH fragment in the other. That is one design strategy applied twice, and it is why two compounds with nothing pharmacologically in common share a structural signature.

The trade-off proline imposes

Constraint cuts both ways. A backbone that cannot adopt many conformations also cannot adopt whichever one a receptor requires unless that happens to be the constrained one. Stability is bought with flexibility, and for a peptide whose activity depends on fitting a binding site, that can be a cost rather than a gain.

Why treating them as a class is useful

Misiura and colleagues review these peptides together because their shared residue produces shared behaviour — resistance to degradation, limited secondary structure, and characteristic handling properties. Recognising the class explains why compounds from unrelated research traditions end up looking structurally similar.

Quick reference

Compound	Prolines	Length	Proportion
Selank	3	7	43%
Semax	2	7	29%
BPC-157	4	15	27%
Typical protein	—	—	~5%

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why is proline used so heavily in these peptides?: It constrains backbone conformation and confers protease resistance, because peptidases recognise a backbone geometry proline does not present.
How enriched are these sequences?: Five to nine times. Proline is about 5% of residues generally; Selank is 43%, Semax 29% and BPC-157 27%.
Is there a downside?: Yes. A constrained backbone cannot adopt whichever conformation a receptor requires unless that happens to be the constrained one.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum